The instinct in ophthalmology marketing is usually to pick a platform and commit. Google or Facebook. Search or social. In practice, the two platforms are good at solving different problems, and the practices getting the best return tend to use them in sequence rather than in isolation — Google first, to find out what to say, and Facebook second, to say it to far more people for less money.

Google search data is, in effect, a free focus group of people already trying to solve the exact problem you treat. When someone types “is cataract surgery worth it” or “why is my night driving getting worse,” they’re handing you their actual words, framed in their own language, at the exact moment they’re motivated enough to act. Search query data shows you not just which keywords get clicks, but which specific phrasing, fears, and framing actually drive someone to act on an ad — insight that’s far harder to generate from a cold-start social campaign with no signal yet. Google’s own guidance to advertisers is explicit that messaging only looks great in theory until it’s tested against real searchers, which is exactly why building a deliberate testing process around ad copy and headlines is treated as a core part of running search campaigns rather than an afterthought.1

This matters more in ophthalmology than in most categories, because the difference between language that converts and language that doesn’t is often the difference between sounding clinical and sounding human. “Premium intraocular lens technology” performs very differently from “see your grandkids’ faces clearly without glasses” — and the only way to know for certain which framing, which fear, and which benefit actually moves a real patient is to test it against real search intent, where the person has already self-identified as having the problem.

Once that language is proven, Facebook is where it should scale — not because Facebook is “cheaper” in some generic sense, but because it solves a different problem than Google ever could. Google captures people who have already decided to search. Facebook and Instagram let you put a proven message in front of people who haven’t searched yet — using interest, behavior, and demographic targeting that has no equivalent in search. For ophthalmology specifically, that means reaching the much larger population who haven’t yet connected their symptoms to a diagnosis, at a lower cost per impression than competing for the same finite pool of in-market search terms.

There’s also a research basis for why the message matters more than the platform once you get there. Independent analysis from Nielsen and NCS on what actually drives sales lift in digital advertising has repeatedly found that creative quality — the actual message and execution — outweighs targeting and media placement as the single biggest factor in performance.2 That finding cuts directly against the instinct to obsess over Facebook’s targeting settings before the message has even been validated. Refining the audience matters. Refining the message first tends to matter more.

The sequence, in practice, looks like this: run a focused Google Search campaign on your highest-intent procedure terms, treating it as a message lab rather than a pure lead-generation engine. Track which headlines, value propositions, and emotional framings produce the strongest click-through and conversion behavior — not just which keywords are cheapest. Once a small number of messages clearly outperform the rest, rebuild your Facebook and Instagram creative around those same proven angles, and let the platform’s much broader targeting apply that validated message to an audience search could never reach in the first place.

Skipping the Google step and going straight to Facebook means guessing at messaging with no real signal behind it. Skipping the Facebook step and staying on Google alone means paying search-auction prices to reach only the narrow slice of the market that’s already decided to look. Used in the right order, each platform does the job the other one can’t.